Assessment criteria for combo packages policy established outline, says Dutch MEB

19 June 2017

Netherlands regulator the Medicines Evaluation Board (MEB) has described the terms and conditions which are to be used to assess applications for combination packages of medicinal products. These terms and conditions can be found in the Assessment criteria for combination packages policy document (MEB 47).

Combination packages are packages which contain more than one medicinal product and are brought to the market under a single trade name and a single marketing authorization. The individual products are different as regards qualitative or quantitative composition and are administered simultaneously or sequentially.

In the Assessment criteria for combination packages policy document (MEB 47) the MEB interprets the terms and conditions which have been established at European level. This relates to:

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK